Vontobel Holding Ltd. Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vontobel Holding Ltd. acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 82,672 shares of the biopharmaceutical company's stock, valued at approximately $1,173,000.

Other large investors have also added to or reduced their stakes in the company. SkyView Investment Advisors LLC purchased a new position in shares of Amicus Therapeutics in the second quarter worth $66,000. Point72 Middle East FZE purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth $81,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Amicus Therapeutics by 97.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 3,638 shares during the last quarter. Belpointe Asset Management LLC increased its position in Amicus Therapeutics by 1,013.1% during the first quarter. Belpointe Asset Management LLC now owns 9,172 shares of the biopharmaceutical company's stock valued at $102,000 after acquiring an additional 8,348 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Amicus Therapeutics during the third quarter valued at $106,000.

Insider Transactions at Amicus Therapeutics

In other news, insider David Michael Clark sold 4,427 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $61,978.00. Following the completion of the transaction, the insider now owns 253,664 shares of the company's stock, valued at $3,551,296. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider David Michael Clark sold 4,427 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $61,978.00. Following the completion of the transaction, the insider now directly owns 253,664 shares of the company's stock, valued at $3,551,296. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman John F. Crowley sold 55,327 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $12.36, for a total value of $683,841.72. Following the transaction, the chairman now directly owns 782,452 shares of the company's stock, valued at $9,671,106.72. The disclosure for this sale can be found here. Insiders sold a total of 103,435 shares of company stock valued at $1,346,447 over the last 90 days. Company insiders own 2.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on FOLD. Cantor Fitzgerald reiterated an "overweight" rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research report on Thursday, February 29th. JPMorgan Chase & Co. reduced their price objective on Amicus Therapeutics from $21.00 to $19.00 and set an "overweight" rating for the company in a research report on Monday, March 18th.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD traded up $0.28 during mid-day trading on Friday, hitting $10.61. 2,888,014 shares of the company traded hands, compared to its average volume of 2,243,154. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -20.80 and a beta of 0.75. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42. The stock's fifty day moving average price is $12.18 and its 200-day moving average price is $12.02. Amicus Therapeutics, Inc. has a one year low of $9.70 and a one year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The business had revenue of $115.08 million during the quarter, compared to the consensus estimate of $115.11 million. Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. Research analysts anticipate that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.